Chimeric Therapeutics partners with Viral Vector Manufacturing Facility to boost GMP viral vector production
Posted: 17 October 2025 Chimeric Therapeutics (ASX:CHM) has signed a Letter of Intent (LOI) with Viral Vector Manufacturing Facility Pty Ltd (VVMF) to establish a strategic partnership focused on the development and Good Manufacturing Practice (GMP) production of…
Led by Monash University, national Connect-TBI initiative to transform care for traumatic brain injury
Posted: 13 October 2025 A new national data asset initiative, Connect-TBI, funded by the Medical Research Future Fund, is set to transform care for Australians experiencing moderate to severe traumatic brain injury (msTBI). The initiative brings together more…
Immuron files FDA application for Phase II trial of oral IMM-529 in C. difficile infection
Posted: 10 October 2025 Immuron announced it has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for a Phase II clinical trial of its oral therapy IMM-529 targeting Clostridioides difficile infection…
Nutromics unveils world-first real-time multiplexed antibiotic monitoring breakthrough
Posted: 10 October 2025 Nutromics has announced a major milestone in wearable diagnostics, unveiling the world’s first real-time, continuous in vivo data for two antibiotics—vancomycin and tobramycin—measured simultaneously on a single device. The breakthrough was presented at the…
Snoretox wins the 2025 Innovation Award at the Animal Health Summit in Kansas city
Posted: 6 October 2025 Snoretox has won the Emerging Company Innovation Award at the global Veterinarian new products conference KCAnimalHealth Summit in the USA. This convention is the leading deal-making convention for veterinary pharmaceutical companies in the USA,…
Chimeric Therapeutics reports tumour reduction in CHM CDH17 Phase 1/2 trial
Posted: 30 September 2025 Chimeric Therapeutics announced further evidence of disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial, following confirmation by the Safety Monitoring Committee that Dose Level 2 is safe for additional…
Monash University partners with South Korea’s K-Bio Lab Hub to establish first Australian biotech launchpad
Posted: 29 September 2025 Monash University announced a new Memorandum of Understanding (MoU) with South Korea’s government-backed biotech incubator, K-Bio Lab Hub, to create the organisation’s first Australian launchpad in Melbourne. The collaboration, centred within the Monash Technology…
RMIT’s 3D-printed diamond titanium device to power next generation implants
Posted: 29 September 2025 RMIT University researchers announced the development of an experimental 3D-printed diamond–titanium device that generated electricity from flowing liquid and wirelessly received power through tissue, allowing remote monitoring of changes in flow. The innovation was…
University of Melbourne awarded $9 million for three new NHMRC Centres of Research Excellence
Posted: 29 September 2025 The University of Melbourne was awarded $9 million in funding for three new Centres of Research Excellence (CREs), designed to address pressing health and sustainability challenges. The funding, announced by the Minister for Health…
Cureator allocates $15.7 million to advance dementia and cognitive decline innovations
Posted: 25 September 2025 The Brandon Capital managed Cureator, in partnership with ANDHealth and Dementia Australia, confirmed the allocation of $15,765,871 to seven companies developing medical technologies for dementia and cognitive decline. The initiative was supported by the…
Starpharma secures $855 million cancer therapy partnership with Genentech
Posted: 25 September 2025 Starpharma announced a landmark global licensing agreement with Genentech, a Roche Group company, to advance cancer treatments using its proprietary DEP® drug delivery platform. The collaboration provided Starpharma with an upfront payment of USD…
CBE Pure Solutions receives TGA licence to manufacture sterile clinical trial liquids for Phase 2 and 3 clinical trials
Posted: 24 September 2025 CBE Pure Solutions has received expanded licence from the Therapeutic Goods Administration (TGA). Their TGA licence now includes sterile fill-and-finish and labelling for injectables and infusions for all clinical trial phases (1-3). In addition,…
